LGG/BB12-pastille Study
Phase 1
Completed
- Conditions
- Probiotics
- Registration Number
- NCT01577485
- Lead Sponsor
- University of Turku
- Brief Summary
We want to study the effect of short-term consumption of probiotics (a mixture of L. rhamnosus GG and B. lactis BB-12)on the composition of the oral flora.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
- Subjects healthy, 20-30 yrs of age
Exclusion Criteria
- Subjects not healthy, too old/young
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Counts of mutans streptococci 4 weeks
- Secondary Outcome Measures
Name Time Method Amount of plaque 4 weeks
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which L. rhamnosus GG and B. lactis BB-12 modulate oral microbiota composition in NCT01577485?
How does the efficacy of LGG/BB12 pastille compare to other probiotic formulations in oral health management?
Which biomarkers correlate with probiotic response in oral flora modulation as studied in NCT01577485?
What are the potential adverse events associated with L. rhamnosus GG and B. lactis BB-12 in short-term oral administration?
Are there synergistic effects when combining LGG/BB12 with prebiotics or other microbiome-targeted therapies for oral health?
Trial Locations
- Locations (1)
Institute of Dentistry
🇫🇮Turku, Finland
Institute of Dentistry🇫🇮Turku, Finland